Mounjaro®
Starting from £179.99/mo
Start journey Learn moreOn day 1 of Mounjaro, you inject 2.5 mg of tirzepatide — the lowest available dose, chosen specifically to give your body time to adjust rather than to produce immediate weight loss. Most people notice little beyond mild nausea or a slightly reduced appetite that first week. Mounjaro is a prescription-only medicine; a clinician will have assessed your suitability before you reach this point. Here is a practical, honest account of what day 1 of Mounjaro typically looks like, and what to do if something feels off.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've got the pen out of the fridge, it's been sitting at room temperature for around 30 minutes, and you're about to do this for the first time. That mild nervousness is normal. The KwikPen is pre-filled — there are no needles to attach, no doses to draw up. You pick a site (most people start with the abdomen), clean the skin, click the pen into place and press. The injection itself takes seconds.
Keep the pen in the fridge door when you're not using it, somewhere you'll see it each week so the routine sticks. The Mounjaro overview covers storage and the full injection process in detail, but the short version is: refrigerated between doses, out for about 30 minutes before you inject, and disposed of carefully after use.
One thing worth knowing before you start: tirzepatide is a dual GIP and GLP-1 receptor agonist, activating two gut-hormone pathways at once. That's why the early dose exists. Jumping straight to a higher strength would likely trigger significant nausea. The 2.5 mg pen is not a lower version of the medicine, it is the correct starting point, as set out in the NHS tirzepatide guidance.
In the first few hours after your injection, many people feel very little at all. That's expected. The medicine doesn't act instantly; tirzepatide takes time to absorb and its effects on appetite and gastric emptying build gradually across the first week and beyond.
Where something is felt, it's usually gastrointestinal: low-grade nausea, a sense of fullness after eating very little, mild indigestion or occasional burping. These are the most commonly reported early side effects and they typically settle within a few days of each dose. Diarrhoea or constipation can appear in the first week too. Fatigue and a mild headache are less common but not unusual on day 1.
Serious reactions on day 1 are rare. Stop and seek medical help urgently if you experience severe stomach pain that spreads to your back, signs of an allergic reaction (swelling, difficulty breathing, rash), or symptoms of severe dehydration from persistent vomiting. The day-by-day Mounjaro guide maps how these patterns tend to shift across the first few weeks as the body adapts. If you're unsure whether what you're experiencing is normal, reporting suspected side effects to the MHRA via the Yellow Card scheme is always an option, and your prescriber is there to advise.
This is the question our prescribers hear most in the first week: why don't I feel any different? The starter dose exists to reduce the chance of the side effects that would otherwise make people stop treatment early. It is not a reflection of how the medicine will eventually work for you.
Clinical trials, including the SURMOUNT-1 study involving thousands of adults, showed average body-weight reductions of around 20–21% at the highest doses over 72 weeks. Those results came after months of gradual titration, not after day 1. The 2.5 mg phase typically lasts four weeks before your prescriber reviews whether to move to the next strength. Progress through the dose schedule is a clinical decision, your prescriber sets the pace based on how you tolerate each level, not a fixed calendar.
For context on what the broader cost of this treatment looks like across a titration course, the Mounjaro cost page covers the UK pricing landscape plainly. And if you want to understand the science behind tirzepatide more fully, the tirzepatide explainer goes deeper on the dual-agonist mechanism.
Day 1 is the hardest in one specific way: you don't yet know how your body responds. By day 2 or day 3, you'll have a clearer picture. Most people find the GI effects peak somewhere in the first 48 hours after the injection and then gradually ease. Eating smaller meals, avoiding fatty or heavily spiced food, and staying hydrated all help during this window.
If nausea is noticeable on day 1, it's worth reading ahead to what day 2 typically brings (or how things usually feel by day 3) so you have a sense of what's transient and what's worth flagging. Some people also report hiccups in the first few days; it's a lesser-known GI effect covered on the Mounjaro hiccups page if you want to check.
The main thing day 1 requires is not heroics, it's simply doing the injection correctly, noting how you feel, and knowing that the routine gets easier quickly. If you haven't started Mounjaro yet and are considering whether it's the right option, a free consultation with our prescribers is the place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.